BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36039444)

  • 21. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.
    Lim JJ; Hooi L; Dan YY; Bonney GK; Zhou L; Chow PK; Chee CE; Toh TB; Chow EK
    J Exp Clin Cancer Res; 2022 Aug; 41(1):249. PubMed ID: 35971164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism.
    Dando I; Pacchiana R; Pozza ED; Cataldo I; Bruno S; Conti P; Cordani M; Grimaldi A; Butera G; Caraglia M; Scarpa A; Palmieri M; Donadelli M
    Free Radic Biol Med; 2017 Dec; 113():176-189. PubMed ID: 28962872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
    Moriceau G; Ory B; Mitrofan L; Riganti C; Blanchard F; Brion R; Charrier C; Battaglia S; Pilet P; Denis MG; Shultz LD; Mönkkönen J; Rédini F; Heymann D
    Cancer Res; 2010 Dec; 70(24):10329-39. PubMed ID: 20971812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
    Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
    Patatsos K; Shekhar TM; Hawkins CJ
    Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
    Pitts TM; Morrow M; Kaufman SA; Tentler JJ; Eckhardt SG
    Mol Cancer Ther; 2009 Feb; 8(2):342-9. PubMed ID: 19174560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
    Xu CX; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    PLoS One; 2011; 6(6):e20899. PubMed ID: 21695126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
    Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
    Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative oncology approach to drug repurposing in osteosarcoma.
    Parrales A; McDonald P; Ottomeyer M; Roy A; Shoenen FJ; Broward M; Bruns T; Thamm DH; Weir SJ; Neville KA; Iwakuma T; Fulbright JM
    PLoS One; 2018; 13(3):e0194224. PubMed ID: 29579058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
    Lei L; Zhang Y; Jian Q; Lei L; Lv N; Williamson RA; Chen P; Zhang D; Hu J
    Exp Physiol; 2021 Feb; 106(2):438-449. PubMed ID: 33336554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Synergistic Antitumor Effect of Everolimus Combined with Gemcitabine on Diffuse Large B-Cell Lymphoma].
    Zuo XQ; Tan CL; Li XM; Ma T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):81-88. PubMed ID: 36765481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
    Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
    IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epoxomicin Sensitizes Resistant Osteosarcoma Cells to TRAIL Induced Apoptosis.
    Hanikoglu F; Cort A; Ozben H; Hanikoglu A; Ozben T
    Anticancer Agents Med Chem; 2015; 15(4):527-33. PubMed ID: 25666501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells.
    Qiu R; Ma G; Li X; Shi Q; Li X; Zhou X; Tang Y; Xie Z; Liao S; Qin Y; Wang R; Ye Y; Luo J; Zhang J
    J Cell Biochem; 2019 Jun; 120(6):10697-10706. PubMed ID: 30652346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.
    Zuo D; Zhou Z; Wang H; Zhang T; Zang J; Yin F; Sun W; Chen J; Duan L; Xu J; Wang Z; Wang C; Lin B; Fu Z; Liao Y; Li S; Sun M; Hua Y; Zheng L; Cai Z
    J Cell Mol Med; 2017 Feb; 21(2):208-221. PubMed ID: 27624867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling.
    Yang F; Nam S; Zhao R; Tian Y; Liu L; Horne DA; Jove R
    Cancer Biol Ther; 2013 Nov; 14(11):1024-31. PubMed ID: 24025361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.